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1. Introduction
Since the advent of coronary angioplasty more than 3 decades ago, the volume of percutane‐
ous coronary interventions (PCI) has been rising progressively, with relative decrease in
amount of coronary artery bypass graft (CABG) surgery. Roughly 1.4 million of catheteriza‐
tion procedures are performed in U.S. each year.[1] Contrast medium is widely used in both
diagnositc coronary angiography and PCI, and intravenous use of iodinated contrast medi‐
um is a common precipitator of contrast-induced nephropathy (or contrast-induced acute
kidney injury [AKI]). [2, 3] With the trend of increasing PCI use in the modern era, expected‐
ly more patients will develop contrast-induced AKI in the future. Currently contrast-in‐
duced nephropathy has been the third most common cause of hospital-acquired AKI in the
large registry studies. [4] This phenomenon is worthy of our attention, since past researchers
have identified that contrast-induced AKI can be associated with increased late incidence of
acute myocardial infarction (AMI) and target vessel revascularization [5], longer in-hospital
stay [6], a more complicated hospitalization course (bleeding episodes requiring transfusion,
vascular complications) [7], and higher in-hospital mortality and morbidity [8-10]. More im‐
portantly, contrast induced AKI correlates with higher healthcare resource utilization in‐
cluding hospitalization cost [11]. The economical spending increases even further if the
episodes of contrast-induced AKI are dialysis-requring.
We  have  witnessed  significant  advancement  in  the  development  of  contrast  medium
within  the  past  7  decades.  [8]  The  structure,  osmolality  and  its  inherent  chemotoxicity
have  also  changed tremendously,  and are  the  focuses  of  experiments  involving various
animal models, cell culture systems, and human subjects. [12] In addition, knowledge of
the pathogenesis and the relevant risk factors of contrast-induced AKI is also expandng,
and  this  progress  contributes  significantly  to  our  planning  of  strategies  to  prevent  this
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adverse event after contrast medium injection. In this sense, a thorough understanding of
the epidemiology, pathophysiology, clinical manifestations, diagnosis, prevention strategy
and management of contrast-induced AKI is of critical importance for both primary care
physicians and intervention cardiologists.
2. Epidemiology of contrast induced acute kidney injury (AKI)
The reported incidence of contrast-induced AKI varies widely among the existing literature,
ranging from 2% to 25% after contrast medium injection [2, 13-15]. The estimations differ ac‐
cording to the cohort being studied, the definition used to identify patients with contrast-
induced AKI, the distinction of the baseline risk factors of the population studied, and the
intervention administered for prevention. [2] Maioli and coworkers, in a randomized con‐
trolled trial (RCT) to evaluate the effectiveness of various preventive strategies, identified a
2~2.5 fold difference in the incidence of contrast-induced AKI (control group, 12%; interven‐
tion group, 27.3%). [16] Weisbord and colleagues, in another study, demonstrated the im‐
portance of the AKI definition to the estimated incidence (ranging from 0.3% if stringently
defined by serum creatinine [sCr] change of 1.0 mg/dL, to 13.7% if loosely defined by sCr
change of 0.25 mg/dL). [3] Consequently, a consistent definition of contrast-induced AKI is
vital for both clinical and research interest in this field.
2.1. Definition of contrast-induced acute kidney injury (AKI)
The definition of contrast-induced AKI can be divided into 2 main components, the pre-
defined time frame and the change of renal function markers (Table 1). Typically contrast-
induced AKI is defined by the current literature as an increase in sCr within the first 24
or 48 hours after contrast injection. [2, 14] There are arguments, however, that a period of
24 hours best captures the group of patients who develop contrast-induced AKI and car‐
ry the most favorable outcome; others claim that the elevation of sCr for clinical dignosis
of contrast-induced AKI takes at least 48 hours. [17] The European Society of Urogenital
Radiology (ESUR) has produced guidelines on contrast-induced AKI in 1999, and updat‐
ed  the  content  in  2011.  [18,  19]  Contrast-induced  AKI  (then  termed  contrast-induced
nephropathy [CIN]) is defined as “a condition in which an impairment in renal function
(an increase in sCr by more than 25% or 0.5 mg/dL) occurs within 3 days following intra‐
vascular administration of a contrast medium, in the absence of an alternative etiology”.
[18] Recently, the threshold of sCr change for diagnosis of AKI has been challenged, since
minor  sCr  change  has  been  shown  to  correlate  with  outcome  measures.  [20]  In  2007,
Acute Kidney Injury Network (AKIN) group has proposed a further fine-tuned classifica‐
tion scheme for staging AKI.  [21] Milder AKI was staged as an elevation of sCre of 0.3
mg/dL within 48 hours. This concept further enhances the diagnostic probability of con‐
trast-induced  nephropathy,  but  there  concerns  that  this  criteria  might  be  over-sensitive
and leads to false positive diagnosis. [22] The researchers are now gradully adopting this
scheme in categorzing contrast-induced AKI.
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease350
Potential Serum markers Time frame
Within 2-4 hours after
procedure
Within 24 hours after
procedure
Within 48 hours after
procedure
Serum creatinine 0.5 mg/dL↑ 0.5 mg/dL↑
Serum creatinine 1.0 mg/dL↑
Serum creatinine 25%↑from baseline 25%↑from baseline
Serum creatinine 50%↑from baseline
Serum cystatin C# ? 25%↑from baseline
Urinary NGAL# ↑>100-150 ng/mL
Abbreviations: NGAL, Neutrophil gelatinase-associated lipocalin
# Still under investigation
Table 1. The currently available definition of contrast-induced nephropathy
Other  rapidly-responsive  serum  markers  aiming  at  earlier  detection  of  renal  function
change also are  under investigation.  Cystatin C is  a  cationic  low molecular  weight  cys‐
teine  protease,  produced  at  a  constant  rate  by  all  nucleated  cells.[23]  It  is  not  metabo‐
lized in the serum, and is freely filtered by glomeruli, thus serving as a good marker for
assessing glomerular  filtration rate  (GFR).[24]  A japanese study utilizing cystatin C and
sCr in evaluating post-computed tomographic coronary angiography AKI concluded that
serum  cystatin  C  at  day  one  after  examination  significantly  correlates  with  change  of
sCr, indicating AKI. [25] Cystatin C is particularly useful in patients with diabetic histo‐
ry. On the other hand, Ribichini et al, in another study comparing sCr and cystatin C for
detecting AKI after PCI within 12 hours, found that serum cystatin C performed signifi‐
cantly worse than sCr, with an area under curve (AUC) value of 0.48 only. [26] Neutro‐
phil  gelatinase-associated  lipocalin  (NGAL)  is  a  small  stress  protein  released  from
injured tubular cells  after various stimuli.  [27] A multitude of studies have documented
its  role  in  earlier  detection  of  AKI,  with  excellent  sensitivity  and  fair  specificity.[28-30]
Hirsch and coworkers first demonstrated in pediatric population that, with a cut-off val‐
ue of 100 ng/mL and timeframe of 2 hours, urinary NGAL predicts contrast-induced AKI
well, with 73% sensitivity and 100% specificity. [31] Another study from Austria reached
similar findings, with additional benefit of improving renal outcome, possibly due to ear‐
lier  detection.  [32]  Besides,  there are other potential  candidate biomarkers implicated as
possessing a role in contrast-induced AKI, including kidney-injury molecules -1 (KIM-1),
urinary L type fatty acid-binding protein (L-FABP), but few human studies are available
currently.[33] Finally, the exact diagnostic modality of choice for contrast-induced nephr‐
opathy  remains  uncertain.  A  recent  study  by  Erselcan  and  colleagues  discovered  that
sCr-based diagnosis can in fact differ substantially from radionuclide-based GFR estima‐
tion method. [34] Consequently,  the reported incidence of contrast-induced nephropathy
in the literature might contain certain degree of deviation. Nonetheless, a close monitor‐
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ing of sCr change and other markers of renal function change after contrast exposure is
still  crucial  and necessary to  detect  any evidence of  contrast-induced nephropathy after
PCI.
3. Risk factors for contrast induced acute kidney injury (AKI)
Identification of patients potentially susceptible of developing contrast-induced AKI before
their exposure is important, since modification of the ways we administer contrast medium
can lead to a decrease in AKI. [4] Risk factors for developing such injury can be divided into
2 parts: patient-related factors and procedure-related factors. We will give a brief overview
of these factors in the following sections.
3.1. Patient-related risk factors
There are several factors identified in the literature that enhances the susceptibility of devel‐
oping contrast-induced AKI (Table 2).
Patient-related risk factors Procedure-related risk factors
Advanced age Higher contrast medium volumes
Diabetes (especially with nephropathy) Higher contrast medium osmolality
Pre-existing CKD Intra-arterial (vs. intravenous) route
Arterial hypotension
Absolute intravascular volume depletion status
Relative intravascular volume depletion status
Diuretic use
NSAID use (?)
ACE inhibitor/ARB use (?)
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease;
NSAID, non-steroidal anti-inflammatory agent
Table 2. Factors associated with increased risk of contrast-induced acute kidney injury
3.1.1. Diabetes mellitus (DM)
DM  has  been  established  as  an  independent  factor  for  patients  developing  contrast-in‐
duced AKI. Presence of DM is associated with a 1.5 ~ 3 fold higher risk of renal injury af‐
ter contrast exposure, and it potentially amplifies the risk incurred by pre-existing chronic
kidney disease (CKD) alone (see below). [13, 15, 35] DM putatively predisposes host kid‐
neys to ischemic injury (from macro- or micro-vascular stenosis), increases oxidatice stress
and free  radical  damage,  as  well  as  endothelial  dysfunction.[36]  The  accompanying  co‐
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morbidities such as coronary artery diseases also contribute to the increased susceptibili‐
ty.  [37]  Fluid retention in DM patients  also increases the use of  diuretics,  which is  also
reportedly a risk factor for contrast-induced AKI. [38] In addition to the impact of a base‐
line DM, pre-procedural  glucose level  higher  than 200 mg/dL s  is  also a  risk  factor  for
contrast-induced AKI (2-fold risk). [39]
3.1.2. Advanced age
Advanced age is another risk factor that enhances the probability of developing contrast-in‐
duced AKI. The definition of advanced age differs between the reported studies, but gener‐
ally a range of 65-75 year-old is adopted. [15] Age higher than 75 can associate with a 1.5-5
fold elevated risk, while every one-year increment carries a 2% increased risk. [7, 15, 35] Ag‐
ing per se denotes the physiologic degeneration of the kidney, both structurally and func‐
tionally, and the ability of recovery after various nephrotoxic insults also dampens in this
population. [40] Most experts agree that a baseline renal function should be measured in
older patients before their exposure to contrast medium. [2, 19]
3.1.3. Pre-existing chronic kidney disease (CKD)
Probably the most important risk factor for contrast-induced AKI is a baseline comorbidity
of CKD. Almost all clinical trials and scoring models for predicting and stratifying risk of
contrast-induced AKI have shown that CKD independently leads to more contrast-induced
AKI episodes. [6, 7, 9, 13, 15, 35] The risk of renal dysfunction is directly proportional to the
baseline sCr value, and further amplified by the presence of DM. [7, 15] Rihal et al, in a large
PCI cohort, identified that patients with pre-procedural sCr 1.2-1.9, 2.0-2.9, >3 mg/dL, had a
graded increment in risk of developing contrast-induced AKI (odds ratio [OR] 2.4, 7.4 and
12.8, respectively).[35] One-third of patients with sCr level higher than 2.0 mg/dL receiving
contrast medium for radiographic studies will develop contrast-induced AKI. [41, 42]
The definition of  CKD seems to  vary somewhat  between studies.  It  is  generally  agreed
that  patients with CKD should be classified by the stages proposed by the Kidney Dis‐
ease  Outcome Quality  Initiative  (KDOQI)  according  to  their  GFR values.  [19]  (Table  3)
CKD  is  usually  defined  as  renal  function  within  stage  3  or  higher  level  based  on  the
KDOQI scheme, but there are some controversy about this. [43] GFR can be estimated by
the Modification of Diet in Renal Disease (MDRD) formula, which takes account of each
patient’s  sCr,  age,  ethnicity  and  gender.  [44]  However,  this  equation  might  be  flawed
when applied in patients with unstable or changing renal function. Patients with special
dietary  preference  such  as  vegetarians  and  high  protein  diets,  and  ones  with  extreme
body stature (very obese or lean) may be unsuitable by MDRD formula, too. [44] Recent‐
ly, Chronic Kidney Disease – Epidemiology Collaboration (CKD-EPI) creatinine equation
is found to outperform MDRD formula in these situations, but this equation, too, does not
apply during changing renal  function.  [45]  Nonetheless,  sCr-based estimation of  GFR is
currently  still  the  most  valuable  and  timely  method of  grading  patients’  baseline  renal
function.  Patients  with  estimated  GFR  (eGFR)  higher  than  60  ml/min/1.73m2  should  be
treated as normal unless they have other renal diseases. [46]
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3.1.4. Arterial hypotension
Hemodynamic instability has been quoted as a risk factor for contrast-induced AKI. [6, 13,
15] This can be demonstrated in certain parameters like hypotension and placement of intra-
aortic balloon pump (IABP). [47] Gruberg and coworkers identified that use of IABP is
linked to a 2 fold increase of developing contrast-induced AKI in patients receiving PCI. [48]
In addition, anemia per se can also be treated in this regard as a factor that reduces tissue
oxygenation and predisposes to CIN. [49]
3.1.5. Absolute intravascular volume depletion (dehydration)
Dehydration is commonly cited as a risk factor for contrast-induced nephropathy. [35, 50,
51] However, few clinical trials actually prove this risk, possibly owing to the fact that dehy‐
dration status is difficult to demonstrate and quantify.
3.1.6. Relative intravascular volume depletion
Statuses such as  congestive heart  failure (CHF) also potentiate  the development of  con‐
trast-induced AKI,  through mechanisms similar to dehydration and absolute intravascu‐
lar volume depletion. [2, 15] CHF is also a risk factor for AKI in critically ill patients. [2]
Most clinical trials have shown than CHF (with a New York Heart Association [NYHA]
grade 3-4)  is  associated with elevated risk of  contrast-induced AKI (OR around 1.5-2.0).
[13, 15, 35] There are also studies showing that AMI within 24 hours of PCI with a low
left ventricular ejection fraction (LVEF) independently predicts occurrence of CIN, with a
80% higher risk. [6, 35]
3.1.7. Drugs (Angiotensin-converting enzyme inhibitors [ACEI], angiotensin-receptor blockers
[ARB], Non-steroidal anti-inflammatory agents [NSAID])
ACEI and ARB, by virtue of their glomerular hemodynamic effect, have been implicated in
predisposing patients to contrast-induced AKI. [42] However, minimal data exists regarding
their actual role in the development of such renal injury. Currently, most available results
are retrospective in nature, and case numbers are low. Umruddin and colleagues, in a small
case control study, demonstrated that use of ACEI or ARB is associated with 2.5-3.0 fold
higher risk of developing CIN after coronary angiography. [52] On the contrary, withdrawal
of ACEI or ARB before coronary procedures does not seem to reduce the risk of contrast-
induced AKI. [53]
NSAIDs are commonly prescribed for analgesic and anti-pyretic purposes, and are notori‐
ous for their adverse impact on cardiovascular outcomes after AMI. [54] Through the inter‐
ruption of intrarenal prostaglandin production, these drugs impede the hemodynamic
regulation of kidney during nephrotoxic insults. Intuitively, they should contribute signifi‐
cantly to contrast-induced nephropathy, but there are very few clinical data currently. A
Brazilian group identified no obvious increase in risk of CIN in patients taking NSAIDs be‐
fore they receive coronary procedures, but the case number was low. [55] Further study is
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warranted before we can conclude that NSAID is neutral or potentially promoting contrast-
induced AKI at this time.
Other  nephrotoxic  agents  such  as  cyclosporin,  tacrolimus,  platinum-based  chemothera‐
peutic regimen can theoretically enhance the susceptibility of the kidney to the insult of
contrast medium. [56] Likewise, few clinical data exists concerning this issue, but physi‐
cians and cardiologists are still advised to refrain from these drugs in patients preparing
for coronary procedures.
3.1.8. Miscellaneous
Elevated high sensitivity CRP has recently been reported as a risk factor for contrast-in‐
duced AKI. [57] The mechanism is putatively related to higher inflammatory status and the
cytokine effect, but this remains speculative. Some researchers also claimed that multiple
myeloma elevates the risk of CIN, but this association is inconsistent among recent studies.
[56, 58, 59] Multiple myeloma by itself might not increase the inherent risk, but patients with
myeloma is frequently dehydrated, and such dehydration could underlie the basis of the
heightened risk. [19]
3.2. Procedure-related risk factors
Procedure-related risk factors include the volume, the osmolality, and the route of contrast
medium administration.
3.2.1. Osmolality of contrast medium
Iodinated contrast media are structurally composed of carbon-based skeletons and iodide
atoms, which render the molecules radiopaque. Contrast media are classified according to
their osmolality into 3 types: high-osmolal (HOCM) (ex. diatrizoate), with an osmolality of
~2000 mOsm/kg; low-osmolal (LOCM)(ex. Iohexol, iopamidol, ioxaglate), with an osmolality
of 600~800 mOsm/kg; and isosmolal (IOCM) (iodixanol), with an osmolality similar to se‐
rum. [2] When the contrast media were first introduced decades ago, only HOCM are avail‐
able for imaging purposes. LOCM/IOCM were later developed in 1980s and 1990s, in order
to reduce the accompanied toxicity incurred by high osmolality. [8] Earlier meta-analysis be‐
fore 1990 demonstrated that the pooled OR for developing CIN decreased substantially after
the introduction of LOCM. [60] High osmolality contrast medium is now an established risk
factor for contrast-induced AKI. [2, 8, 14, 19] IOCM has been shown to possess the lowest
risk for contrast -induced AKI in patients with CKD, but different IOCM agents do not seem
to display clinically different effect. [61-64] A systemic review performed several years ago
found that IOCM possess the lowest risk of contrast-induced AKI. [64] However, several
clinical trials done in recent years yielded conflict results, with similar CIN rates between
IOCM and LOCM agents. [65, 66] Despite these controversies, the American College of Car‐
diology (ACC) /American Heart Association (AHA) guidelines for the management of pa‐
tients with acute coronary syndrome (ACS) list IOCM as a class I recommendation. [67]
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3.2.2. Volume of contrast medium
The volume of administered contrast medium can be another important factor regarding
the risk of contrast-induced AKI. Multiple studies have identified that the mean contrast
volume  is  an  independent  predictor  of  CIN.  [5,  9,  15]  Even  small  volumes  of  contrast
medium (~30ml) might trigger renal injury in high-risk patients. [68] For every 100ml in‐
crease  in  the  amount  of  contrast  medium used,  there  is  a  concomitant  12% increase  of
the risk.  [35]  Several  groups proposed that  the volume of  contrast  administered should
not exceed twice the number of a given patient’s baseline eGFR value (in mililiter), while
others found that adjustment of the contrast volume to one’s body weight and sCr level
could minimize the risk. [2, 69]
3.2.3. Route of contrast medium administration
Circumstantial evidence has pointed out that intra-arterial injection of contrast medium car‐
ries a higher risk of contrast-induced AKI than intravenous use. [15, 70] However, no mech‐
anisms have been provided to explain this phenomenon. [2] Some speculative reasons are as
follows: the dose used in intravenous enhancement for computed tomography (CT) is usual‐
ly lower than that for arteriography; patients who received contrast-enhanced CT are usual‐
ly less hemodynamically unstable than ones receiving intra-arterial studies; intra-arterial
angiography may incidentally incur atheroembolism, which would not be expected to hap‐
pen in intravenous studies. [2, 19] There are also reports suggesting that patients who were
at-risk for intra-arterial procedures might not be at-risk for intravenous studies. [3] Nonethe‐
less, based upon the available evidence, it is prudent to evaluate patients regarding the exact
necessity, risk and benefit for intra-arterial or intravenous procedures. If both indications ex‐
ist with equal risk-benefit ratio, a choice of intravenous administration of contrast medium
might be better.
4. Clinical course and pathophysiology of contrast-induced AKI
The norm of contrast-induced nephropathy is that sCr begins to rise within 24 hours after
contrast medium administration, peaks at 3-5 days, and returns to baseline level or near
baseline within 1-3 weeks. [71] It has been shown that even transient rise of sCr can asso‐
ciate with longer hospital stay. [42] Most patients developing contrast-induced AKI do not
require dialysis; however, they do have poorer short-term and long-term survival. [9, 48]
Gruberg et al, in a large cohort of patients with CIN after coronary angiography, reported
that only 0.4% require hemodialysis after AKI occurs, but those necessitating dialytic sup‐
port have particularly higher mortality (12-35%). [42, 48]
The pathophysiologic sequence of contrast-induced AKI includes a pre-existing impaired re‐
nal function, and the superimposed acute events consisting of vasoactive mediator-related
vasoconstriction, triggered by iodinated contrast medium. [2] Besides, experimental studies
also suggest that contrast-induced nephropathy can be a combination of both: renal ische‐
mia and the direct tubulotoxicity exerted by contrast medium. [42]
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4.1. Renal ischemia
Animal studies showed that contrast medium intravascular injection can increase the activi‐
ty of a variety of vasoactive substances, including vasopressin, angiotensin II, dopamine-1,
endothelin and adenosine, while decrease the activity of renal vasodilators such as nitric ox‐
ide and prostaglandins. [72, 73] Other mechanisms include high osmolality-related renal
blood flow decrease, and the enhanced erythrocyte aggregation induced by contrast medi‐
um. [74, 75] This decrease in renal blood flow and GFR after exposure to contrast medium is
frequently severer in dehydrated animals than euvolemic ones. [76] In particular, renal me‐
dulla is more susceptible to ischemic insult than renal cortex, and contrast medium has been
reported to cause shunting of blood flow to the cortex. [77]
4.2. Direct tubulotoxicity
The tubulotoxicity of contrast medium can be demonstrated in the pathological changes it
induces, including epithelial vacuolization, cellular necrosis or apoptosis and interstitial in‐
flammation. [78] Contrast medium can additionally reduce antioxidant enzyme activity
within the kidney of experimental animals, and free radical mediated cytotoxicity of the re‐
nal tubular cells has been detected in these models. [78] The higher osmolality of contrast
medium can also contribute to its epithelial cell toxicity. The osmolar-driven solute diuresis
with subsequent tubuloglomerular feedback activation can theoretically reduce GFR, and in‐
creased tubular hydrostatic pressures might cause compression of surrounding microvascu‐
latures, leading to a decrease in GFR. [42] In an in vitro cell model, apoptosis (presenting as
DNA fragmentation) was found to increase in cells exposed to hyperosmolar contrast me‐
dia, with the degree of fragmentation proportional to the osmolality of contrast media. [79]
Consequently, contrast medium possesses direct tubulotoxicity not only through the induc‐
tion of oxidative stress and cellular injury, but also through the hyperosmolality it carries. It
would be interesting to speculate whether the available isosmotic contrast media can reduce
the renal abnormality displayed by exposure to their high osmolar and low osmolar coun‐
terparts, but there seems to be no difference. [80] A plausible reason is that isosmolar con‐
trast medium still has increased viscosity and might cause more tubular cell vacuolization
and cessation of renal microcirculation. [81]
5. Risk prediction and modeling
Many research groups have strived to devise predictive models for patients with high risk
of developing contrast-induced AKI. Mehran and colleagues developed a simple scoring
method that integrates 8 baseline clinical variables to evaluate the risk of CIN after PCI.
These variables include advanced age (defined as age > 75), hypotension, CHF, anemia, DM,
CKD (defined as sCr > 1.5 mg/dL), use of IABP and procedural factors (volume of contrast
medium), each with different score. [15] Risk categories are divided into low, moderate,
high, and very high. They found that the incidence of contrast-induced AKI ranges from
7.5% in the low risk category, to 57.3% in the very high risk category. Bartholomew and
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coworkers, in another large cohort of post-PCI CIN patients, derived a risk scoring scheme
composed of DM, CHF, hypertension, peripheral vascular disease, IABP uses, CKD (defined
as creatinine clearance < 60 ml/min), and procedural factors (urgent or emergency proce‐
dures, contrast volume ≧260ml). [13] Incidence of CIN ranged from 0.5% in the lowest risk
category, to 43% in the highest risk category. These studies did prove that the risk factors
identified previously are mutually additive, and the risk of contrast-induced AKI increases
prominently as risk factors accumulate. However, none of the reported studies have been
prospectively applied to different populations, and the utility in real-world is still in ques‐
tion. It is currently inappropriate to recommend the routine use of these models in risk strat‐
ification of specific population [2], but we should bear in mind that the more risk factors our
patients possess, the higher risk he/she might develop AKI after receiving PCI.
6. Strategies of prevention for contrast-induced AKI
6.1. Modification of risk factors
Some of the patients’ baseline comorbidities cannot be changed (eg. DM, CHF, etc.), but oth‐
ers are potentially modifiable to reduce the risk of developing CIN. First, the selection of the
patients for PCI can be important. Patients with unstable hemodynamic status or circulatory
collapse are at high-risk of developing contrast-induced AKI, and and the risk/benefit ratio
needs to be carefully weighed for these patients. [42] The clinical need for PCI should be
scrutinized, and the in-charge cardiologist or hospitalist should consider whether another
procedure without the use of iodinated contrast media can act as a substitute. [59] Nonethe‐
less, in the setting of emergency procedures (like primary PCI), where the benefit of very
early intervention outweighs the risk of waiting for the results of the blood test, it is still nec‐
essary to proceed without available sCr. [2] When possible, it is still desirable to obtain a
pre-procedural blood sample for sCr, since the likelihood of impaired renal function pre-
procedurally can increase the subsequent risk of developing CIN and other adverse events.
Second, patients with DM, HTN, CHF or potentially changing renal function should receive
a pre-procedural baseline renal function testing (if they have not received one before), and if
possible, a nephrology/radiology specialist consultation could be obtained. [2] Hyperglyce‐
mic status should be properly managed before procedure. Agents such as NSAIDs, diuretics
(if feasible), and possibly ACEIs should be discontinued 1-2 days before administration of
contrast media. [42] Finally, if PCI or diagnostic coronary angiography is warranted, the
amount of contrast medium volume should be as little as possible, and the choice of contrast
medium should be iso-osmolar or low osmolar agents, especially in patients with high risk.
[2, 8, 14, 42] Repeated exposure should be delayed for 48 hours in patients at-risk of devel‐
oping contrast-induced AKI, and an even longer delay if patients are diabetic or have pre-
existing CKD. [42] Ideally, the interval between procedures should be 2 weeks, the expected
recovery time for kidney after an acute insult, but frequently this is not possible, especially
in patients with AMI and complicating courses. [19] In this situation, the interval should still
be as long as clinically acceptable.
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6.2. Volume expansion
There is broad consensus that volume expansion (through isotonic saline hydration) is capa‐
ble of reducing the risk of contrast-induced nephropathy. The putative benefit of adequate
volume expansion includes improving renal blood flow, inducing diuresis with dilution of
contrast medium within renal tubules, suppression of the renin-angiotensin-aldosterone sys‐
tem, lowering the secretion of arginine vasopressin, and less reductions in the renal produc‐
tion of endogenous vasodilators (nitric oxide, prostaglandin). [82] However, firm evidence
regarding the benefit of volume expansion is not available and not expected to exist, since
randomized, double-blinded trials comparing hydration and a control group without hydra‐
tion cannot be perfomed for lack of ethical acceptability.
6.2.1. Route of volume expansion
The route of volume expansion has been debated. Earlier expert group consensus suggested
that intravenous hydration is more favorable than oral hydration [18], but clinical evidence
seemed conflicting. Trivedi and coworkers prospectively evaluated the efficacy of unrestrict‐
ed oral fluids or intravenous normal saline for 24 hours (at a rate of 1ml/kg/hr, 12 hours be‐
fore and 12 hours after procedures) in a small group of elective PCI patients. [83] Contrast-
induced AKI occurred significantly less frequently in the intravenous hydration group than
the oral fluid group (3.7% vs. 34.6%). Dussol et al perfomed another study comparing intra‐
venous normal saline (at a rate of 15 ml/kg for 6 hours before procedure) to oral salt tablet
(1g/10kg body weight for 2 days before procedure) in a moderately-sized cohort receiving
various radiologic studies. [84] Oral salt supplement was found to be as effective as intrave‐
nous saline hydration for the prevention of contrast-induced AKI. However, the pre-proce‐
dural fasting policy routinely instituted in some groups might make oral salt tabley not
feasible. Nonetheless, most groups currently use intravenous hydration for volume expan‐
sion purposes in clinical practice.
6.2.2. Formula of hydration
Currently the most popular and effective solution for preventing CIN is isotonic saline
(0.9%). Earlier studies comparing saline and other solutions including mannitol or mannitol
with furosemide have demonstrated the superiority of saline infusion. [85, 86] The strategy
of forced diuresis is also not favored by existing evidence. In the PRINCE study (Prevention
of Radiocontrast Induced Nephropathy Clinical Evaluation), Stevens and coworkers found
no benefit from forced diuresis with intravenous crystalloid, furosemide, mannitol or low-
dose dopamine therapy, compared with hydration alone in at-risk patients. [86] The lack of
benefit of mannitol and furosemide might come from their renal untoward effects, including
osmotic diuresis-related increase of renal oxygen consumption, vasoconstrictor effect of
mannitol and diuretic-induced hypovolemia. [42] In addition, Mueller et al, in a large group
of patients receiving PCI, compared the strategy of siotonic saline (0.9%) infusion to half-iso‐
tonic saline infusion (0.45%, + plus 5% glucose) starting one day before procedures. [87] Iso‐
tonic hydration is superior to half-isotonic hydration in the efficacy for prevention of
contrast-induced AKI.
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The issue of sodium bicarbonate for preventing contrast-induced AKI is also controversial. It
is suggested that sodium bicarbonate might result in urine alkalinization and reduce the
generation of free radical through scavenging reactive oxygen species. [19] Bicarbonate can
also increase urine flow, while on the contrary, the large amount of chloride from isotonic
saline infusion may lead to constriction of the renal vasculature. [88] Merten and colleagues
first performed a pilot study comparing sodium bicarbonate (154 mEq/L in dextrose 5% wa‐
ter at a rate of 3ml/kg/hour) started one hour before procedure and continued for six hours
after (at a rate of 1ml/kg/hour), to infusion of sodium chloride at a similar rate. [89] The
more favorable effect of sodium bicarbonate prophylaxis inspired multiple follow-up stud‐
ies focusing on similar issues, with more-or-less similar results. Several metanalysis con‐
cluded that sodium bicarbonate is more effective than sodium chloride in protecting against
CIN, but the heterogeneity of included studies exist, with even publication bias in some
studies. [88, 90] Besides, the lower risk of contrast-induced AKI does not seem to translate
into lower mortality or less need for dialytic support. [91] The potential risk of al kalemia
induced by sodium bicarbonate infusion in patients with CHF and electrolyte disturbance
(hypocalcemia, hypokalemia) is another concern. Nonetheless, based upon existing evi‐
dence, sodium bicarbonate serves as an equal or even better choice for prevention of con‐
trast-induced AKI, compared with sodium chloride. [19]
6.2.3. Amount and rate of volume expansion
There is currently no clear evidence for the optimal rate and duration of volume expansion.
Correlation with patients’ body weight seems reasonable, and expert consensus agrees that
1.0-1.5 ml/kg/hour of infusion is appropriate. [19] However, there are clinical trials compar‐
ing overnight hydration before elective procedures to bolus hydration immediately before
the procedures, and continuous hydration seems to provide better protection. [92] It is rec‐
ommended now that intravenous hydration should start 12 hours before PCI or coronary
angiography and continue for 12 hours after, at a rate provided above. [19]
6.3. Pharmacological prophylaxis
Other than intravenous hydration, pharmacologic prophylaxis for at-risk patients against
CIN has been tested with multiple drugs, but currently no single agent is approved specifi‐
cally for this purpose. [19] Several candidate drugs have been attempted, with conflicting re‐
sults. We will briefly review these drugs in the following section.
6.3.1. N-acetylcysteine (NAC)
NAC has been the center of investigation during the last decade. It possesses antioxidant
and potentially vasodilatory properties. [8] Usually NAC is given orally but intravenous
formula is  also available,  and owing to its  low price,  the availability is  also high.  NAC
has minimal side effects and is generally considered safe. The most common protocol of
NAC is to give this agent orally 600mg twice a day for 24 hours on the day before and
the day of procedure. [19]
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More than 30 randomized controlled trials have been performed regarding the efficacy of
NAC for  preventing  contrast-induced  AKI,  and  most  studies  involve  patients  receiving
PCI or  diagnostic  coronary angiography.  The results  are conflicting,  with some display‐
ing  lower  incidence  of  CIN,  while  others  demonstrating  no  significant  benefit.  [93-95]
Some researchers proposed that higher dose NAC might be more effective than standard
dose NAC [96],  but we should remind ourselves that  intravenous NAC at higher doses
might be associated with significant side effects (hypotension, bronchospasm, etc.) Meta-
analysis of  existing studies also display conflicting results,  depending on the studies in‐
cluded.  [97-99]  However,  most  studies  are  under-powered,  and  the  beneficial  effect  of
NAC is mostly deducted by earlier studies,  with small  size and lower quality.  [19] Fur‐
thermore,  there  have  been  observations  that  NAC  might  lower  sCr  without  affecting
GFR, devoid of benefit to renal function. [100] In conclusion, the benefit of NAC in pre‐
venting contrast-induced AKI remains unproven, and the use of NAC should be careful‐
ly weighed against the potential side effects listed above.
6.3.2. Fenoldopam
Fenoldopam mesylate is  a  selective dopamine-1 receptor agonist  that  produces systemic
and renal  artery vasodilatation.  [42]  It  is  found to exhibit  desirable  renal  effects  includ‐
ing decrease in renal vascular resistance and increase in renal blood flow, GFR, with na‐
triuresis.  Small-group  studies  have  identified  potential  benefit  of  fenoldopam  with
normal saline in the amelioration of  renal  blood flow reduction caused by contrast  me‐
dia,  but  this  is  not  validated  in  a  subsequent  large,  multicenter,  double-blind  random‐
ized  placebo-controlled  trial.  [101]  It  is  also  found  to  perform  inferiorly  to  NAC  in
several controlled trials. [102] Currently, the routine use of fenoldopam to protect against
contrast-induced AKI could not be recommended.
6.3.3. Theophylline
Theophylline, through cyclic AMP generation, is found to relieve the renal vasoconstrictive
reponse to contrast media injection potentially mediated by adenosine in animal models.
[103] Multiple investigators have evaluated the competitive adenosine antagonists, theo‐
phylline and aminophylline as candidate agents for reducing the risk of CIN. A meta-analy‐
sis concluded that prophylactive theophylline use appears to protect against contrast-
induced AKI, but the included trials are few, and publication bias is likely. [103] There are
also studies suggesting the superiority of theophylline over NAC. [104] Further evaluation
is needed in this regrad. Significant side effect resulting from use of theophylline is rarely
observed during short-term use and if serum concentration being kept low.
6.3.4. Ascorbic acid
Ascorbic acid is a potent, water-soluble antioxidant capable of scavening reactive oxygen
species that potentially introduces damage to vital macromolecules. Ascorbic acid has been
shown to attenuate renal damage from various types of insult, including post-ischemic
stress, cisplatin-related and aminoglycoside-related injury in animal models. [105] It also
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possesses extensive safety record as a harmless dietary supplement. Randomized controlled
trials utilizing oral ascorbic acid as a prophylactive strategy for reducing CIN have been per‐
formed, and the results appear to be positive. [106] Boscheri et al, in a small cohort, failed to
display benefit of ascorbid acid. [107] In this sense, definite conclusion also can not be made
at this time, owing similarly to low case numbers and somewhat flawed study design.
6.3.5. Statin
Statin, also hydroxymethylglutaryl coenzymeA reductase (HMG-CoA) inhibitor, improves
the lipid profiles of patients, and has reportedly pleiotropic effects on vasculature, including
decreasing low-density lipoprotein (LDL), lipid peroxidation, improving inflammation, low‐
ering risk of cellular necrosis and elevated collagen content in human plaques. [108] Statin
therapy significantly reduces cardiovascular mortality and morbidity in patients with hy‐
perlipidemia, and post-procedural statin also is shown to reduce cardiovascular events in
patients receiving PCI. [109] Although the exact mechanism by which statin reduces iodinat‐
ed contrast media-induced AKI is still unclear, it is likely that one of the anti-oxidation, anti-
inflammatory, and anti-thrombotic effects can be the principle reason. [110] In a large group
of PCI patients, statin use was found to reduce incidence of CIN (OR 0.87). [110] Patti et al
further demonstrated that pre-procedural statin use not only prevents against contrast-in‐
duced AKI but also leads to a better long-term survival after 4 years of follow-up. [111] Sev‐
eral recent meta-analyses yielded conflicting results, and some researchers proposed that
statin might be helpful mostly in patients with more advanced CKD. [112, 113] Thus, it re‐
mains unknown whether statins is beneficial for preventing contrast-induced AKI at
present, and further clinical trials are awaited to determine the specific group of patients
that acquire the most benefit from statin use.
6.3.6. Iloprost
Iloprost is a stable prostaglandin I2 (prostacyclin) analogue, which exerts renal vasodilatory
effect and has been shown to protect animal kidneys against ischemic and toxic insults. [114]
Development of contrast-induced AKI might partially originate from attenuation of the re‐
nal prostacylin response, and thus iloprost is theoretically beneficial for the prevention of
CIN. Spargias and coworkers first conducted a pilot study on iloprost, with a regimen of 1-2
ng/kg/min infusion from 30-90 minutes before procedures and continuing until 4 hours after
procedures, for prevention of CIN. [115] The result was promising. Subsequent larger con‐
firmatory trials yielded similarly positive findings. [116] However, these results were all
produced by a single group, and other researchers have not been able to replicate their find‐
ings. The other drawbacks of iloprost are its tolerability issues. [116] Further studies are
needed to affirm the role of iloprost in our armamentarium against contrast-induced AKI.
6.3.7. Miscellaneous
There is limited evidence regarding low-dose dopamine, calcium channel blockers, atrial na‐
triuretic peptides, L-arginine, endothelin antagonists in their roles in the prevention of con‐
trast-induced nephropathy. [19]
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7. Conclusion
Contrast-induced AKI, or contrast-induced nephropathy, is a growing issue in the contem‐
porary field of intervention cardiology and also in fields like diagnostic radiology. Although
the definitions of contrast-induced AKI are still changing with the advancement of new bio‐
markers reflecting renal function and injury, the most popular and cost-effective method is
still serum creatinine. As the understanding of the pathogenesis of CIN also progresses,
more and more strategies for prevention of contrast-induced AKI are being developed and
tested clinically. It will be vital for primary care physicians and cardiologists to carefully se‐
lect their patients as candidates of contrast medium containing procedures, knowledgeably
stratify the risk, and implicate evidence-based prophylactic means to reduce the incidence of
contrast-induced AKI.
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